



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						
Sheet 1 of 1			Application Number	09/704,306		
			Filing Date	November 2, 2000		
			First Named Inventor	James P. Beck		
			Art Unit	1624		
			Examiner Name	Brenda L. Coleman		
			Attorney Docket Number	2809/1371		
U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
BC	1	US-4,564,613	01-14-1986	Boltze et al.	class 514 subclass 222	
BC	2	US-6,579,885	06-17-2003	Beck et al.	514 307	
BC	3	US-6,911,453	06-28-2005	Hofmeister et al.	514 307	
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
BC	4	WO 02/04455 A2	01-17-2002	Beck et al.		
xx BC	5	EP 0 140 070 A1	05-08-1985	Boltze et al.		(English abstract)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
BC	6	BURROWS et al., "Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review," <i>J. Clin. Psychiatry</i> 59 (Suppl. 14):4-7 (1998) (98819-76-2 REGISTRY (Reboxetine))				
BC	7	DESAI et al., "Relationship Between in Vivo Occupancy at the Dopamine Transporter and Behavioral Effects of Cocaine, GBR 12909 [1-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and Benzotropine Analogs," <i>JPET</i> 315(1):397-404 (2005)				
BC	8	HYTTEL, "Pharmacological Characterization of Selective Serotonin Reuptake Inhibitors (SSRIs)," <i>Int. Clin. Psychopharmacol.</i> 9(Suppl. 1):19-26 (1994) (61869-08-7 REGISTRY (Paroxetine); 59729-32-7 REGISTRY (Citalopram); 79559-97-0 REGISTRY (Sertraline); 54910-89-3 REGISTRY (Fluoxetine); 54739-18-3 REGISTRY (Fluvoxamine))				
BC	9	KAMETANI et al., "Studies on the Synthesis of Heterocyclic Compounds-DXCI," <i>Tetrahedron</i> 31:235-238 (1975)				
BC	10	MÜLLER, "Current St. John's Wort Research from Mode of Action to Clinical Efficacy," <i>Pharmacological Research</i> 47:101-109 (2003)				
Examiner Signature	Brenda Coleman			Date Considered	August 9, 2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

10006539.1

xx structures only